Lite Strategy (LITS) investor relations material

Executive summary

• Changed name to Lite Strategy, Inc. and shifted focus from oncology drug development to a Litecoin Treasury Strategy, deploying PIPE proceeds into Litecoin as a primary reserve asset.

• Discontinued clinical development of voruciclib and zandelisib, with ongoing assessment of pre-clinical activities and potential future research.

• Board and executive leadership changes occurred in connection with strategic alternatives review and operational wind-down.

• Closed a $100 million PIPE in July 2025, issuing common stock and pre-funded warrants, and entered agreements with asset managers and advisors for digital asset deployment.

Financial highlights

• Fiscal year ended June 30, 2025, reported a net loss of $15.9 million, compared to net income of $17.8 million in the prior year.

• No revenue recognized in FY25; prior year included $65.3 million from the KKC agreement, which was terminated.

• Research and development expenses decreased to $3.9 million from $16.6 million year-over-year due to program discontinuations.

• General and administrative expenses fell to $13.5 million from $23.3 million, reflecting workforce reductions and lower overhead.

• Cash and cash equivalents at June 30, 2025, were $18.0 million.

Outlook and guidance

• Current cash balance expected to fund operations for at least the next 12 months.

• Future R&D expenses will increase if pre-clinical development resumes.

• Ongoing evaluation of further investigational research and potential expansion into Litecoin mining.